Download

Download Full Text (2.9 MB)

Description

Psoriasis is a chronic inflammatory skin disease marked by keratinocyte hyperproliferation and immune dysregulation. Verrucous psoriasis, a rare variant, presents with thick, hyperkeratotic, wart-like plaques that are often refractory to standard treatments. Secukinumab, a monoclonal antibody targeting IL-17A, has demonstrated efficacy in plaque psoriasis, but data on its use in verrucous psoriasis is limited. This case highlights complete remission of verrucous psoriasis with secukinumab.

Publication Date

5-9-2024

Disciplines

Dermatology

Comments

2024 Alvin Yarrows Research Day at Corewell Health Hospital Farmington Hills, Farmington Hills, MI, May 9, 2024.

Verrucous Psoriasis Treated with Secukinumab

Included in

Dermatology Commons

Share

COinS